Novo Nordisk A/S Sponsored ADR (NVO)
Why Novo Nordisk's Weight Loss Pill Has Taken Off
Novo Nordisk's weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke with patients about their experience on the pill and explains how the drug is facing competition from Eli Lilly's oral weight loss pill.
Can Wegovy HD 7.2 mg drive Novo Nordisk's obesity drug rebound?
Novo Nordisk announced on Tuesday that it is making a higher-dose version of its popular weight-loss medication, Wegovy, available across the United States. The new 7.2-milligram dose, branded as Wegovy HD, was recently approved under the FDA Commissioner's National Priority Review Voucher program last month, marking a significant development in obesity treatment options.
Trump's Iran deadline, the Altman-Musk feud, Novo's Wegovy pill and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
One of the world's leading healthcare names, Novo Nordisk (NYSE:NVO) cut prices on Wegovy and Ozempic by up to 48% in India at the start of April 2026, a direct response to low-cost generic semaglutide flooding the market.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day.
Novo Nordisk: Competing In A Duopoly
Novo Nordisk A/S (NVO) faces intense competition from Eli Lilly in the fast-growing GLP-1 market, impacting its growth outlook and valuation. NVO's future growth hinges on defending market share with new GLP-1 products, including oral Wegovy, higher-dose Wegovy, and an innovative pipeline. Despite a strong pipeline, NVO's current injectable offerings lag Eli Lilly's, and upcoming patent expirations raise sustainability concerns.
NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
Novo Nordisk stock jumps after launching a Wegovy subscription plan to cut costs, expand telehealth access and improve treatment adherence for sustained obesity care.
British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks
UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's Wegovy to reduce the risk of serious heart problems or strokes in obese or overweight adults, becoming the first GLP-1 drug to be endorsed for this use.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk: Why I Still Find It An Interesting Opportunity
Novo Nordisk has experienced a sharp 28% YTD and 53% 12-month decline, creating a potentially attractive entry point. Despite macro uncertainty and weakening obesity drug demand, NVO trades at a multi-year low valuation and appears technically oversold. I maintain a Buy rating, viewing the recent sell-off as unjustified by fundamentals and the long-term obesity treatment thesis as intact.
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
